Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting

Gašparović, Hrvoje and Petričević, Mate and Kopjar, Tomislav and Đurić, Željko and Svetina, Lucija and Biočina, Bojan (2014) Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting. American Journal of Cardiology, 113 (10). pp. 1660-1667. ISSN 0002-9149

PDF - Accepted Version
Download (1MB) | Preview


Coronary artery bypass grafting is pivotal in the contemporary management of complex coronary artery disease. Interpatient variability to antiplatelet agents, however, harbors the potential to compromise the revascularization benefit by increasing the incidence of adverse events. This study was designed to define the impact of dual antiplatelet therapy (dAPT) on clinical outcomes among aspirin-resistant patients who underwent coronary artery surgery. We randomly assigned 219 aspirin-resistant patients according to multiple electrode aggregometry to receive clopidogrel (75 mg) plus aspirin (300 mg) or aspirin-monotherapy (300 mg). The primary end point was a composite outcome of all-cause death, nonfatal myocardial infarction, stroke, or cardiovascular hospitalization assessed at 6 months postoperatively. The primary end point occurred in 6% of patients assigned to dAPT and 10% of patients randomized to aspirin-monotherapy (relative risk 0.61, 95% confidence interval 0.25 to 1.51, p = 0.33). No significant treatment effect was noted in the occurrence of the safety end point. The total incidence of bleeding events was 25% and 19% in the dAPT and aspirin-monotherapy groups, respectively (relative risk 1.34, 95% confidence interval 0.80 to 2.23, p = 0.33). In the subgroup analysis, dAPT led to lower rates of adverse events in patients with a body mass index >30 kg/m(2) (0% vs 18%, p <0.01) and those <65 years (0% vs 10%, p = 0.02). In conclusion, the addition of clopidogrel in patients found to be aspirin resistant after coronary artery bypass grafting did not reduce the incidence of adverse events, nor did it increase the number of recorded bleeding events. dAPT did, however, lower the incidence of the primary end point in obese patients and those <65 years.

Item Type: Article
MeSH: Aged ; Aspirin/administration & dosage ; Coronary Artery Bypass ; Coronary Artery Disease/therapy ; Croatia/epidemiology ; Dose-Response Relationship, Drug ; Drug Resistance ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Humans ; Incidence ; Male ; Platelet Aggregation Inhibitors/administration & dosage ; Postoperative Care/methods ; Postoperative Complications/epidemiology ; Retrospective Studies ; Survival Rate/trends ; Ticlopidine/administration & dosage ; Ticlopidine/analogs & derivatives ; Treatment Outcome
Departments: Katedra za kirurgiju
Depositing User: Marijan Šember
Status: Published
Gašparović, HrvojeUNSPECIFIED
Petričević, MateUNSPECIFIED
Kopjar, TomislavUNSPECIFIED
Svetina, LucijaUNSPECIFIED
Date: 15 May 2014
Date Deposited: 16 Sep 2015 09:57
Last Modified: 16 Jul 2020 09:50
Subjects: /
Related URLs:

Actions (login required)

View Item View Item


Downloads per month over past year